FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 02/2025”.
The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.
As of the end of February 2025 we identified the following current VC trends in the United States:
- Total Healthcare & Life Sciences funding reached EUR 6,893m (+14% vs. 2024)
- After a strong start in January with a 64% year-over-year increase, healthcare and life sciences funding in the U.S. has significantly slowed in February
- Biotech/Pharma received 51% of the total investment volume (EUR 3,543m) with immunology being the leading indication (26%)
- In February Eikon Therapeutics secured the highest transaction volume with EUR 337m, followed by Abridge with EUR 240m and Abcuro with EUR 193m
- Accelmed (United States) is the most active investor (by deal volume in 2025), followed by Y Combinator (United States) and F-Prime Capital (United States)
To access the full report, please click here.